Merck to initiate new clinical programme with lower dose of daily oral Islatravir in combination with Doravirine for HIV-1 treatment Read more
Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1 treatment in virologically suppressed adults Read more